Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
PLoS Negl Trop Dis ; 14(2): e0007982, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-32012162

RESUMO

BACKGROUND: Government of India is committed to eliminate measles and control rubella/congenital rubella syndrome (CRS) by 2020. In 2016, CRS surveillance was established in five sentinel sites. We analyzed surveillance data to describe the epidemiology of CRS in India. METHODOLOGY/PRINCIPAL FINDINGS: We used case definitions adapted from the WHO-recommended standards for CRS surveillance. Suspected patients underwent complete clinical examination including cardiovascular system, ophthalmic examination and assessment for hearing impairment. Sera were tested for presence of IgM and IgG antibodies against rubella. Of the 645 suspected CRS patients enrolled during two years, 137 (21.2%) were classified as laboratory confirmed CRS and 8 (1.2%) as congenital rubella infection. The median age of laboratory confirmed CRS infants was 3 months. Common clinical features among laboratory confirmed CRS patients included structural heart defects in 108 (78.8%), one or more eye signs (cataract, glaucoma, pigmentary retinopathy) in 82 (59.9%) and hearing impairment in 51. (38.6%) Thirty-three (24.1%) laboratory confirmed CRS patients died over a period of 2 years. Surveillance met the quality indicators in terms of adequacy of investigation, adequacy of sample collection for serological diagnosis as well as virological confirmation. CONCLUSIONS/SIGNIFICANCE: About one fifth suspected CRS patients were laboratory confirmed, indicating significance of rubella as a persistent public health problem in India. Continued surveillance will generate data to monitor the progress made by the rubella control program in the country.


Assuntos
Síndrome da Rubéola Congênita/epidemiologia , Adolescente , Adulto , Anticorpos Antivirais/sangue , Feminino , Humanos , Imunoglobulina M/sangue , Índia/epidemiologia , Lactente , Recém-Nascido , Masculino , Síndrome da Rubéola Congênita/sangue , Síndrome da Rubéola Congênita/diagnóstico , Síndrome da Rubéola Congênita/mortalidade , Vigilância de Evento Sentinela , Adulto Jovem
2.
Hum Vaccin Immunother ; 15(2): 309-316, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30285537

RESUMO

Since 2011, GAVI, The Vaccine Alliance, has funded eligible countries to introduce rubella-containing vaccination (RCV) into their national schedule. Two key indicators used to monitor the impact - the future deaths and DALYs (Disability Adjusted Life Years) averted through vaccination conducted in specific periods - are poorly understood for rubella and Congenital Rubella Syndrome (CRS). We calculate these indicators using an age-structured dynamic transmission model for rubella, with historical vaccination coverage projections during 2001-30 in 92 low and middle-income countries considered most likely to require global support to achieve the Global Vaccine Action Plan's objectives. 131,000 CRS deaths and 12.5 million DALYs may be prevented with immunization campaigns at best-estimate coverage during 2001-30, relative to those without additional support. The impact depended on the time period considered and the method for attributing deaths averted to vaccination in specific periods. The analyses support ongoing activities to reduce CRS-related morbidity and mortality.


Assuntos
Vacina contra Sarampo-Caxumba-Rubéola/uso terapêutico , Complicações Infecciosas na Gravidez/prevenção & controle , Anos de Vida Ajustados por Qualidade de Vida , Síndrome da Rubéola Congênita/mortalidade , Síndrome da Rubéola Congênita/prevenção & controle , Feminino , Saúde Global , Humanos , Modelos Teóricos , Morbidade , Pobreza , Gravidez , Complicações Infecciosas na Gravidez/microbiologia , Vacinação , Cobertura Vacinal
3.
Vaccine ; 25(1): 1-9, 2007 Jan 02.
Artigo em Inglês | MEDLINE | ID: mdl-17262908

RESUMO

The WHO Steering Committee reviewed and evaluated the progress towards global control of measles and rubella and provided guidelines for future research activities concerning both diseases during its meeting in New Delhi, in April 2005. Global measles vaccination coverage increased from 71% in 1999 to 76% in 2004 and indigenous transmission was interrupted or kept at very low levels in many countries. However, Africa and Southeast Asia continue to experience endemic transmission and high mortality rates, despite a global mortality reduction of 39% between 1999 and 2003. On the basis of reports from countries with continued indigenous measles virus transmission, future control strategies as well as advantages and potential drawbacks of global measles eradication were discussed. Similarly the burden of rubella and congenital rubella syndrome (CRS) as well as the cost-effectiveness of rubella vaccination was assessed using different methods in several countries without vaccination programs. As measles and rubella viruses continue to circulate surveillance and control strategies need further optimization. RT-PCR was considered as an alternative method for laboratory diagnosis of CRS. The value of dried blood spots and oral fluid as alternative samples for measles and rubella IgG and IgM detection and genotype determination was evaluated. However further validation of these methods in different settings is required before their routine use can be recommended.


Assuntos
Vacina contra Sarampo/administração & dosagem , Sarampo , Síndrome da Rubéola Congênita , Vacina contra Rubéola/administração & dosagem , Rubéola (Sarampo Alemão) , Adolescente , Adulto , Criança , Feminino , Humanos , Sarampo/epidemiologia , Sarampo/mortalidade , Sarampo/prevenção & controle , Vírus do Sarampo/classificação , Vírus do Sarampo/genética , Vírus do Sarampo/imunologia , Gravidez , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/mortalidade , Rubéola (Sarampo Alemão)/prevenção & controle , Síndrome da Rubéola Congênita/diagnóstico , Síndrome da Rubéola Congênita/epidemiologia , Síndrome da Rubéola Congênita/mortalidade , Síndrome da Rubéola Congênita/prevenção & controle , Vírus da Rubéola/classificação , Vírus da Rubéola/genética , Vírus da Rubéola/imunologia , Vacinação/economia , Organização Mundial da Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...